NorthWest Biotherapeutics Inc (NWBO)

[hyperopia]

Thanks for the article Hbpainter. I liked this part:

“The findings provide clues as to why existing cancer treatments fail to stop glioblastoma growth. “If you understand that this is a disease with multiple states driving it, each one with a corresponding favorite cancer gene, you understand better why targeting one gene at a time has failed so far, and you can dissect the mechanisms of adaptation and resistance to therapies,” said Suvà.”

It reminded me of Linda Powers’ presentation at the Phacilitate Conference when she explained that “the approach taken by the Company’s DCVax therapies uses Nature’s system and is the opposite of a “silver bullet” approach:  i.e., many active agents against many targets, rather than a single active against just one or a few tumor targets.” 

And Ms. Powers also noted that, “in addition to Glioblastoma, other types of solid tumors also involve extensive variations and corresponding treatment challenges.  To date, only limited numbers of patients (e.g., 5-30% for various cancers) have been reported to respond to immune therapies for solid tumors, including checkpoint inhibitors.  In light of the extensive variation among solid tumors, a patient’s version of a cancer may or may not express a particular single target or couple of targets.”

In that presentation, she really set the stage for the next evolution in cancer treatment, i.e. the era of the DC cancer vaccine.